Entries by Michael Kuhrt

New CEO at Morphosys

Germany-based MorphoSys AG announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer. The appointment will take effect on September 1, 2019.

New CEO for Valo Therapeutics

Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the company’s inception in 2017.

Healthier and sustainable food ingredients from biotech

As food producers are taking up current health and sustainability trends more and more, the next EFIB (30 September??2 October, 2019) will see a lot of technology providers and ingredient producers showcasing biotechnological solutions in Brussels. European Biotechnology spoke with Dr Gerhard Schmid, Head, Wacker Biosolutions, about the market, challenges, and growth strategies within the bioeconomy.

ReViral Appoints Alex C. Sapir as CEO

ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).

Patent Ineligibility Initiative

By Ute Kilger, Patent Attorney, European Patent and Trade Mark Attorney, Boehmert & Boehmert Anwaltspartnerschaft mbB
The Life Science Industry needs a strong, predictable, reliable patent system that incentivizes innovations in order to bring new drugs and diagnostics to the patient, drives innovations and prevents patent abuse. The US Supreme Court has rendered a series of decisions about patent eligibility (§101 of the Patent Act) that make entire parts of Life Science Technology ineligible for patent protection and/or renders granted patents unenforceable. This makes the patent system unreliable and unpredictable and averse to investment into innovations.   Change will need to come from Congress. Recently, a group of Senators and Representatives of the US Congress released the draft text of a bipartisan, bi­cameral proposal to reform Section 101 of the Patent Act. The initiative to reform Section 101 of the Patent Act needs political support from all life science stakeholders including from those in Biotech.

Paul Hudson to become Sanofi CEO

At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.

Emergency on planet AMR: a vital pipeline to protect

The recently released IACG report testifies that the antimicrobial resistance (AMR) problem is now receiving some echo at the political level. Literature exploring ways to fix the acknowledged market failure is growing. Stakeholder meetings deciphering the impact of the proposed models are being organised all over the world. Still, time is against us.

Dietmar Berger returns to big pharma

Sanofi has a new head of development, which the company confirmed on Wednesday with a short tweet: "Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients."